Cargando…
Recurrent Respiratory Papillomatosis (RRP)—Meta-analyses on the use of the HPV vaccine as adjuvant therapy
Recurrent Respiratory Papillomatosis(RRP) is a rare disease with severe morbidity. Treatment is surgical. Prevailing viewpoint is that prophylactic HPV vaccines do not have therapeutic benefit due to their modus operandi. Studies on HPV vaccination alongside surgery were meta-analysed to test effect...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10067830/ https://www.ncbi.nlm.nih.gov/pubmed/37005390 http://dx.doi.org/10.1038/s41541-023-00644-8 |
_version_ | 1785018557727244288 |
---|---|
author | Goon, Peter Sauzet, Odile Schuermann, Matthias Oppel, Felix Shao, SenYao Scholtz, Lars-Uwe Sudhoff, Holger Goerner, Martin |
author_facet | Goon, Peter Sauzet, Odile Schuermann, Matthias Oppel, Felix Shao, SenYao Scholtz, Lars-Uwe Sudhoff, Holger Goerner, Martin |
author_sort | Goon, Peter |
collection | PubMed |
description | Recurrent Respiratory Papillomatosis(RRP) is a rare disease with severe morbidity. Treatment is surgical. Prevailing viewpoint is that prophylactic HPV vaccines do not have therapeutic benefit due to their modus operandi. Studies on HPV vaccination alongside surgery were meta-analysed to test effect on burden of disease. Databases were accessed Nov and Dec 2021 [PubMed, Cochrane, Embase and Web of Science]. Main outcome measured was: Mean paired differences in the number of surgeries or recurrences per month. Analyses was performed using: Random effect maximal likelihood estimation model using the Stata module Mataan(StataCorp. 2019. Stata Statistical Software: Release 16. College Station, TX:StataCorp LLC.) Our results found n = 38 patients, suitable for syntheses with one previous meta-analyses (4 published, 2 unpublished studies) n = 63, total of n = 101 patients. Analyses rendered an overall reduction of 0.123 recurrences or surgeries per month (95% confidence interval [0.064, 0.183]). Our meta-analyses concludes that HPV vaccine is a beneficial adjunct therapy alongside surgery |
format | Online Article Text |
id | pubmed-10067830 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-100678302023-04-04 Recurrent Respiratory Papillomatosis (RRP)—Meta-analyses on the use of the HPV vaccine as adjuvant therapy Goon, Peter Sauzet, Odile Schuermann, Matthias Oppel, Felix Shao, SenYao Scholtz, Lars-Uwe Sudhoff, Holger Goerner, Martin NPJ Vaccines Article Recurrent Respiratory Papillomatosis(RRP) is a rare disease with severe morbidity. Treatment is surgical. Prevailing viewpoint is that prophylactic HPV vaccines do not have therapeutic benefit due to their modus operandi. Studies on HPV vaccination alongside surgery were meta-analysed to test effect on burden of disease. Databases were accessed Nov and Dec 2021 [PubMed, Cochrane, Embase and Web of Science]. Main outcome measured was: Mean paired differences in the number of surgeries or recurrences per month. Analyses was performed using: Random effect maximal likelihood estimation model using the Stata module Mataan(StataCorp. 2019. Stata Statistical Software: Release 16. College Station, TX:StataCorp LLC.) Our results found n = 38 patients, suitable for syntheses with one previous meta-analyses (4 published, 2 unpublished studies) n = 63, total of n = 101 patients. Analyses rendered an overall reduction of 0.123 recurrences or surgeries per month (95% confidence interval [0.064, 0.183]). Our meta-analyses concludes that HPV vaccine is a beneficial adjunct therapy alongside surgery Nature Publishing Group UK 2023-04-01 /pmc/articles/PMC10067830/ /pubmed/37005390 http://dx.doi.org/10.1038/s41541-023-00644-8 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Goon, Peter Sauzet, Odile Schuermann, Matthias Oppel, Felix Shao, SenYao Scholtz, Lars-Uwe Sudhoff, Holger Goerner, Martin Recurrent Respiratory Papillomatosis (RRP)—Meta-analyses on the use of the HPV vaccine as adjuvant therapy |
title | Recurrent Respiratory Papillomatosis (RRP)—Meta-analyses on the use of the HPV vaccine as adjuvant therapy |
title_full | Recurrent Respiratory Papillomatosis (RRP)—Meta-analyses on the use of the HPV vaccine as adjuvant therapy |
title_fullStr | Recurrent Respiratory Papillomatosis (RRP)—Meta-analyses on the use of the HPV vaccine as adjuvant therapy |
title_full_unstemmed | Recurrent Respiratory Papillomatosis (RRP)—Meta-analyses on the use of the HPV vaccine as adjuvant therapy |
title_short | Recurrent Respiratory Papillomatosis (RRP)—Meta-analyses on the use of the HPV vaccine as adjuvant therapy |
title_sort | recurrent respiratory papillomatosis (rrp)—meta-analyses on the use of the hpv vaccine as adjuvant therapy |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10067830/ https://www.ncbi.nlm.nih.gov/pubmed/37005390 http://dx.doi.org/10.1038/s41541-023-00644-8 |
work_keys_str_mv | AT goonpeter recurrentrespiratorypapillomatosisrrpmetaanalysesontheuseofthehpvvaccineasadjuvanttherapy AT sauzetodile recurrentrespiratorypapillomatosisrrpmetaanalysesontheuseofthehpvvaccineasadjuvanttherapy AT schuermannmatthias recurrentrespiratorypapillomatosisrrpmetaanalysesontheuseofthehpvvaccineasadjuvanttherapy AT oppelfelix recurrentrespiratorypapillomatosisrrpmetaanalysesontheuseofthehpvvaccineasadjuvanttherapy AT shaosenyao recurrentrespiratorypapillomatosisrrpmetaanalysesontheuseofthehpvvaccineasadjuvanttherapy AT scholtzlarsuwe recurrentrespiratorypapillomatosisrrpmetaanalysesontheuseofthehpvvaccineasadjuvanttherapy AT sudhoffholger recurrentrespiratorypapillomatosisrrpmetaanalysesontheuseofthehpvvaccineasadjuvanttherapy AT goernermartin recurrentrespiratorypapillomatosisrrpmetaanalysesontheuseofthehpvvaccineasadjuvanttherapy |